Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspectives in Medicinal Chemistry

Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options

Author(s): Laura Nunes Silva, Thaís Pereira de Mello, Lívia de Souza Ramos, Marta Helena Branquinha, Maryam Roudbary and André Luis Souza dos Santos*

Volume 20, Issue 22, 2020

Page: [1951 - 1957] Pages: 7

DOI: 10.2174/156802662022200917110102

Next »
[1]
Li, X.; Xu, S.; Yu, M.; Wang, K.; Tao, Y.; Zhou, Y.; Shi, J.; Zhou, M.; Wu, B.; Yang, Z.; Zhang, C.; Yue, J.; Zhang, Z.; Renz, H.; Liu, X.; Xie, J.; Xie, M.; Zhao, J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. Allergy Clin. Immunol., 2020, 146(1), 110-118.
[2]
Zheng, Z.; Peng, F.; Xu, B.; Zhao, J.; Liu, H.; Peng, J.; Li, Q.; Jiang, C.; Zhou, Y.; Liu, S.; Ye, C.; Zhang, P.; Xing, Y.; Guo, H.; Tang, W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect., 2020, 81(2), e16-e25.
[3]
Hughes, S.; Troise, O.; Donaldson, H. Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting. Clin. Microbiol. Infect., 2020.. (In press)
[4]
Zhu, X.; Ge, Y.; Wu, T.; Zhao, K.; Chen, Y.; Wu, B.; Zhu, F.; Zhu, B.; Cui, L. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res., 2020, 285, 198005-198005.
[5]
Schauwvlieghe, A.F.A.D.; Rijnders, B.J.A.; Philips, N.; Verwijs, R.; Vanderbeke, L.; Van Tienen, C.; Lagrou, K.; Verweij, P.E.; Van de Veerdonk, F.L.; Gommers, D.; Spronk, P.; Bergmans, D.C.J.J.; Hoedemaekers, A.; Andrinopoulou, E.R.; van den Berg, C.H.S.B.; Juffermans, N.P.; Hodiamont, C.J.; Vonk, A.G.; Depuydt, P.; Boelens, J.; Wauters, J. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir. Med., 2018, 6(10), 782-792.
[6]
Lamoth, F.; Calandra, T. Let’s add invasive aspergillosis to the list of influenza complications. Lancet Respir. Med., 2018, 6(10), 733-735.
[7]
Huang, J.; Li, H.; Lan, C.; Zou, S.; Zhang, H.; Wang, X.; Weng, H. Concomitant severe influenza and cryptococcal infections: A case report and literature review. Medicine (Baltimore), 2019, 98(19)e15544
[8]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[9]
Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223), 507-513.
[10]
Cox, M.J.; Loman, N.; Bogaert, D.; O’Grady, J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe, 2020, 1(1), e11-e11.
[11]
Kosmidis, C.; Denning, D.W. The clinical spectrum of pulmonary aspergillosis. Thorax, 2015, 70(3), 270-277.
[12]
Jenks, J.D.; Hoenigl, M. Treatment of Aspergillosis. J. Fungi (Basel), 2018, 4(3), 98.
[13]
Brown, G.D.; Denning, D.W.; Levitz, S.M. Tackling human fungal infections. Science, 2012, 336(6082), 647.
[14]
Wang, J.; Yang, Q.; Zhang, P.; Sheng, J.; Zhou, J.; Qu, T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit. Care, 2020, 24(1), 299.
[15]
Du, Y.; Tu, L.; Zhu, P.; Mu, M.; Wang, R.; Yang, P.; Wang, X.; Hu, C.; Ping, R.; Hu, P.; Li, T.; Cao, F.; Chang, C.; Hu, Q.; Jin, Y.; Xu, G. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am. J. Respir. Crit. Care Med., 2020, 201(11), 1372-1379.
[16]
Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; Yu, T.; Wang, Y.; Pan, S.; Zou, X.; Yuan, S.; Shang, Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med., 2020, 8(5), 475-481.
[17]
Koehler, P.; Cornely, O.A.; Böttiger, B.W.; Dusse, F.; Eichenauer, D.A.; Fuchs, F.; Hallek, M.; Jung, N.; Klein, F.; Persigehl, T.; Rybniker, J.; Kochanek, M.; Böll, B.; Shimabukuro-Vornhagen, A. COVID-19 associated pulmonary aspergillosis. Mycoses, 2020, 63(6), 528-534.
[18]
Alanio, A.; Dellière, S.; Fodil, S.; Bretagne, S.; Mégarbane, B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir. Med., 2020, 8(6), e48-e49.
[19]
Rutsaert, L.; Steinfort, N.; Van Hunsel, T.; Bomans, P.; Naesens, R.; Mertes, H.; Dits, H.; Van Regenmortel, N. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care, 2020, 10(1), 71-71.
[20]
Blaize, M.; Mayaux, J.; Nabet, C.; Lampros, A.; Marcelin, A.G.; Thellier, M.; Piarroux, R.; Demoule, A.; Fekkar, A. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg. Infect. Dis., 2020, 26(7), 1636-1637.
[21]
Meijer, E.F.J.; Dofferhoff, A.S.M.; Hoiting, O.; Buil, J.B.; Meis, J.F. Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report. J. Fungi (Basel), 2020, 6(2), 79.
[22]
Prattes, J.; Valentin, T.; Hoenigl, M.; Talakic, E.; Reisinger, A.C.; Eller, P. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. Med. Mycol. Case Rep., 2020. . (In press)
[23]
Lescure, F-X.; Bouadma, L.; Nguyen, D.; Parisey, M.; Wicky, P.H.; Behillil, S.; Gaymard, A.; Bouscambert-Duchamp, M.; Donati, F.; Le Hingrat, Q.; Enouf, V.; Houhou-Fidouh, N.; Valette, M.; Mailles, A.; Lucet, J.C.; Mentre, F.; Duval, X.; Descamps, D.; Malvy, D.; Timsit, J.F.; Lina, B.; van-der-Werf, S.; Yazdanpanah, Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect. Dis., 2020, 20(6), 697-706.
[24]
van Arkel, A.L.E.; Rijpstra, T.A.; Belderbos, H.N.A.; van Wijngaarden, P.; Verweij, P.E.; Bentvelsen, R.G. COVID-19–associated pulmonary aspergillosis. Am. J. Respir. Crit. Care Med., 2020, 202(1), 132-135.
[25]
Antinori, S.; Rech, R.; Galimberti, L.; Castelli, A.; Angeli, E.; Fossali, T.; Bernasconi, D.; Covizzi, A.; Bonazzetti, C.; Torre, A.; Carsana, L.; Tonello, C.; Zerbi, P.; Nebuloni, M. Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge. Travel Med. Infect. Dis., 2020, 101752-101752. (In press)
[26]
Lahmer, T.; Rasch, S.; Spinner, C. Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia. Clin Microbiol Infect , 2020, S1198-1743X(1120), 30309-30308.
[27]
Santana, M.F.; Pivoto, G.; Alexandre, M.A.A.; Baía-da-Silva, D.C.; Borba, M.G.D.S.; Val, F.A.; Brito-Sousa, J.D.; Melo, G.C.; Monteiro, W.M.; Souza, J.V.B.; Pinheiro, S.B.; Ferreira, L.C.L.; Naveca, F.G.; Nascimento, V.A.; Corado, A.L.G.; Hajjar, L.A.; Silva Neto, J.R.; Siva, G.A.V.; Pasqualotto, A.C.; Lacerda, M.V.G. Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev. Soc. Bras. Med. Trop., 2020, 53, e20200401-e20200401.
[28]
Nasir, N.; Farooqi, J.; Mahmood, S.F.; Jabeen, K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses, 2020, 63(8), 766-770.
[29]
Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.; S., Perlin, D. Lass-Flörl, C.; Hoenigl, M. . COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J. Fungi (Basel), 2020, 6(2), 91.
[30]
Ullmann, A.J.; Aguado, J.M.; Arikan-Akdagli, S. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect., 2018, 24(Suppl. 1), e1-e38.
[31]
Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis. Nat. Rev. Dis. Primers, 2018, 4(1), 18026.
[32]
Agrifoglio, A.; Cachafeiro, L.; Figueira, J.C.; Añón, J.M.; García de Lorenzo, A. COVID-19 and fungal co-infections: We must keep them in mind. J. Mycol. Med., 2020. . In press
[33]
Seitz, T.; Hoepler, W.; Weseslindtner, L.; Aberle, J.H.; Aberle, S.W.; Puchhammer-Stoeckl, E.; Baumgartner, S.; Traugott, M.; Karolyi, M.; Pawelka, E.; Niculescu, I.; Friese, E.; Neuhold, S.; Stahl, D.; Madl, C.; Zoufaly, A.; Wenisch, C.; Laferl, H. Successful management of the first reported case in Austria of COVID-19 with ARDS. Infection, 2020, 48(4), 647-651.
[34]
Nori, P.; Cowman, K.; Chen, V.; Bartash, R.; Szymczak, W.; Madaline, T.; Punjabi Katiyar, C.; Jain, R.; Aldrich, M.; Weston, G.; Gialanella, P.; Corpuz, M.; Gendlina, I.; Guo, Y. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect. Control Hosp. Epidemiol., 2020. . (In press)
[35]
Vila, T.; Sultan, A.S.; Montelongo-Jauregui, D.; Jabra-Rizk, M.A. Oral candidiasis: a disease of opportunity. J. Fungi (Basel), 2020, 6(1), 15.
[36]
Intra, J.; Sarto, C.; Beck, E. Bacterial and fungal colonization of the respiratory tract in COVID-19 patients should not be neglected. Am J Infect Control, , 2020, S0196-6553 (0120), 30566 -30566.
[37]
Salehi, M.; Ahmadikia, K.; Mahmoudi, S.; Kalantari, S.; Jamalimoghadamsiahkali, S.; Izadi, A.; Kord, M.; Dehghan Manshadi, S.A.; Seifi, A.; Ghiasvand, F.; Khajavirad, N.; Ebrahimi, S.; Koohfar, A.; Boekhout, T.; Khodavaisy, S. Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern. Mycoses, 2020, 63(8), 771-778.
[38]
Ventoulis, I.; Sarmourli, T.; Amoiridou, P.; Mantzana, P.; Exindari, M.; Gioula, G.; Vyzantiadis, T.A. Bloodstream infection by Saccharomyces cerevisiae in two covid-19 patients after receiving supplementation of Saccharomyces in the ICU. J. Fungi (Basel), 2020, 6(3), 98.
[39]
Amorim Dos Santos, J.; Normando, A.G.C.; Carvalho da Silva, R.L.; De Paula, R.M.; Cembranel, A.C.; Santos-Silva, A.R.; Guerra, E.N.S. Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? Int. J. Infect. Dis., 2020, 97, 326-328.
[40]
White, P.L.; Price, J.S.; Backx, M. Therapy and management of Pneumocystis jirovecii infection. J. Fungi (Basel), 2018, 4(4), 127.
[41]
Menon, A.A.; Berg, D.D.; Brea, E.J.; Deutsch, A.J.; Kidia, K.K.; Thurber, E.G.; Polsky, S.B.; Yeh, T.; Duskin, J.A.; Holliday, A.M.; Gay, E.B.; Fredenburgh, L.E. A case of COVID-19 and Pneumocystis jirovecii coinfection. Am. J. Respir. Crit. Care Med., 2020, 202(1), 136-138.
[42]
Mang, S.; Kaddu-Mulindwa, D.; Metz, C.; Becker, A.; Seiler, F.; Smola, S.; Maßmann, A.; Becker, S.L.; Papan, C.; Bals, R.; Lepper, P.M.; Danziger, G. Pneumocystis Jirovecii Pneumonia and SARS-CoV-2 Co-Infection in newly diagnosed HIV-1 infection. Clin. Infect. Dis., 2020 . (In press)
[43]
Shah, A.S.; Heidari, A.; Civelli, V.F. The coincidence of 2 epidemics, Coccidioidomycosis and SARS-CoV-2: A case report. J. Investig. Med. High Impact Case Rep., 2020. . (In press)
[44]
Silva, L.N.; de Mello, T.P.; de Souza Ramos, L.; Branquinha, M.H.; Dos Santos, A.L.S. Current challenges and updates on the therapy of fungal infections. Curr. Top. Med. Chem., 2019, 19(7), 495-499.
[45]
Chowdhary, A.; Sharma, C.; Meis, J.F. Azole-resistant aspergillosis: Epidemiology, molecular mechanisms, and treatment., , J Infect Dis, 2017, 216(suppl_3), S436-S444.
[46]
Perlin, D.S. Echinocandin resistance in Candida. Clin. Infect. Dis., 2015, 61(6)(Suppl. 6), S612-S617.
[47]
Cai, S.; Sun, W.; Li, M.; Dong, L. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. Clin. Rheumatol., 2020, 39(9), 2797-2802.
[48]
Antinori, S.; Bonazzetti, C.; Gubertini, G.; Capetti, A.; Pagani, C.; Morena, V.; Rimoldi, S.; Galimberti, L.; Sarzi-Puttini, P.; Ridolfo, A.L. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun. Rev., 2020, 19(7), 102564-102564.
[49]
Morena, V.; Milazzo, L.; Oreni, L.; Bestetti, G.; Fossali, T.; Bassoli, C.; Torre, A.; Cossu, M.V.; Minari, C.; Ballone, E.; Perotti, A.; Mileto, D.; Niero, F.; Merli, S.; Foschi, A.; Vimercati, S.; Rizzardini, G.; Sollima, S.; Bradanini, L.; Galimberti, L.; Colombo, R.; Micheli, V.; Negri, C.; Ridolfo, A.L.; Meroni, L.; Galli, M.; Antinori, S.; Corbellino, M. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur. J. Intern. Med., 2020, 76, 36-42.
[50]
Campochiaro, C.; Della-Torre, E.; Cavalli, G.; De Luca, G.; Ripa, M.; Boffini, N.; Tomelleri, A.; Baldissera, E.; Rovere-Querini, P.; Ruggeri, A.; Monti, G.; De Cobelli, F.; Zangrillo, A.; Tresoldi, M.; Castagna, A.; Dagna, L.; Angelillo, P.; Assanelli, A.; Baldissera, E.; Boffini, N.; Calvisi, S.; Campochiaro, C.; Canetti, D.; Cariddi, A.; Castagna, A.; Cavalli, G.; Ciceri, F.; Dagna, L.; De Cobelli, F.; De Luca, G.; Torre, E.D.; Farina, N.; Fazio, M.; Landoni, G.; Mancuso, G.; Marinosci, A.; Monti, G.; Oltolini, C.; Ripa, M.; Rovere-Querini, P.; Ruggeri, A.; Sartorelli, S.; Scarpellini, P.; Spessot, M.; Tomelleri, A.; Tresoldi, M.; Zangrillo, A.
[51]
Armstrong-James, D.; Youngs, J.; Bicanic, T.; Abdolrasouli, A.; Denning, D.W.; Johnson, E.; Mehra, V.; Pagliuca, T.; Patel, B.; Rhodes, J.; Schelenz, S.; Shah, A.; van de Veerdonk, F.L.; Verweij, P.E.; White, P.L.; Fisher, M.C. Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA). Eur. Respir. J., 2020. . (in press).

Rights & Permissions Print Cite
Article Metrics
27
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy